NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

SARS-COV2 Pandemic Serosurvey in a Rare Disease Population

Completed

Conditions: SARS-COV2 Virus

First Posted Date: 2020-10-30

Last Posted Date: 2024-08-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 730

Registration Number: NCT04609085

Locations: 🇺🇸
National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, Maryland, United States
🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Defining the COVID-19 Immunity Denominator in the Mekong: a Cross-Sectional Seroprevalence Study of SARS-CoV-2 in HealthyVolunteers

Withdrawn

Conditions: Healthy Volunteers

First Posted Date: 2020-10-20

Last Posted Date: 2021-10-04

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Registration Number: NCT04594395

Locations: 🇰🇭
National Malaria Center (CNM), Ministry of Health (MOH), Phnom Penh, Cambodia
🇰🇭
Cambodian Center for Communicable Disease (CCDC), Ministry of Health (MOH), Phnom Penh, Cambodia

COVID-19: Pediatric Research Immune Network on SARS-CoV-2 and MIS-C

Completed

Conditions: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Multisystem Inflammatory Syndrome in Children (MIS-C)
Coronavirus Disease 2019 (COVID-19)

Interventions: Other: SARS-CoV-2 and/or MIS-C Exposure

First Posted Date: 2020-10-19

Last Posted Date: 2024-02-29

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 244

Registration Number: NCT04588363

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States

and more 17 locations

ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19

Phase 2

Completed

Conditions: COVID-19

Interventions: Biological: Lenzilumab
Other: Placebo
Drug: Remdesivir

First Posted Date: 2020-10-12

Last Posted Date: 2023-06-05

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 527

Registration Number: NCT04583969

Locations: 🇺🇸
Stony Brook Medicine - Stony Brook University Hospital, Stony Brook, New York, United States
🇺🇸
University of Utah - Infectious Diseases, Salt Lake City, Utah, United States
🇺🇸
Hoag Hospital Newport Beach, Newport Beach, California, United States

and more 52 locations

Send-In Sample Collection for Comprehensive Analyses of Innate and Adaptive Immune Responses During Acute COVID-19 and Convalescence

Recruiting

Conditions: COVID-19 Infection

First Posted Date: 2020-10-12

Last Posted Date: 2024-06-11

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 500

Registration Number: NCT04582903

Locations: 🇺🇸
Niaid/Lcim, Rockville, Maryland, United States

ACTIV-5 / Big Effect Trial (BET-A) for the Treatment of COVID-19

Phase 2

Completed

Conditions: COVID-19

Interventions: Other: Placebo
Biological: Risankizumab
Drug: Remdesivir

First Posted Date: 2020-10-12

Last Posted Date: 2023-05-16

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 214

Registration Number: NCT04583956

Locations: 🇺🇸
Kern Medical Center, Bakersfield, California, United States
🇺🇸
Emory Vaccine Center - The Hope Clinic, Decatur, Georgia, United States
🇺🇸
Boston Medical Center - Center for Infectious Diseases - Shapiro Center, Boston, Massachusetts, United States

and more 29 locations

PK and Safety of Remdesivir for Treatment of COVID-19 in Pregnant and Non-Pregnant Women in the US

Completed

Conditions: COVID-19

Interventions: Drug: Remdesivir

First Posted Date: 2020-10-09

Last Posted Date: 2023-06-09

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 54

Registration Number: NCT04582266

Locations: 🇺🇸
Bronx-Lebanon Hospital Center (Site #: 5114), Bronx, New York, United States
🇺🇸
David Geffen School of Medicine at UCLA (Site #: 5112), Los Angeles, California, United States
🇺🇸
Pediatric Perinatal HIV Clinical Trials Unit (Site #: 5127), Miami, Florida, United States

and more 7 locations

Dose, Safety, Tolerability and Immunogenicity of an Influenza H10 Stabilized Stem Ferritin Vaccine, VRC-FLUNPF0103-00-VP, in Healthy Adults

Phase 1

Completed

Conditions: Influenza

Interventions: Biological: VRC-FLUNPF0103-00-VP (H10ssF-6473)

First Posted Date: 2020-10-08

Last Posted Date: 2023-02-22

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 25

Registration Number: NCT04579250

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

The Influence of Malnutrition, Diabetes Mellitus, and Helminth Infections on Biosignatures in Latent Tuberculosis in a South Indian Population

Active, not recruiting

Conditions: Mycobacterium Tuberculosis
Diabetes Mellitus
Malnutrition
LTBI (Latent TB Infection)
Helminth Infections

First Posted Date: 2020-08-26

Last Posted Date: 2024-07-31

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 626

Registration Number: NCT04526613

Locations: 🇮🇳
National Institute for Research In Tuberculosis, International Centers for Exel, Chennai, India

Evaluating the Infectivity, Safety and Immunogenicity of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine, LID/ΔM2-2/1030s, in RSV-Seronegative Infants and Children 6 to 24 Months of Age

Phase 1

Active, not recruiting

Conditions: RSV Infection

Interventions: Biological: RSV LID/ΔM2-2/1030s
Biological: Placebo

First Posted Date: 2020-08-20

Last Posted Date: 2024-07-15

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 81

Registration Number: NCT04520659

Locations: 🇺🇸
John Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States
🇺🇸
Vanderbilt University, Nashville, Tennessee, United States
🇺🇸
University of Rochester Medical Center, Rochester, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy